MONARCH 3 Results: Abemaciclib Improves PFS in Advanced Breast Cancer

Share this content:
Researchers evaluated the safety and efficacy of abemaciclib plus a non-steroidal AI vs an AI alone among patients with hormone receptor–positive, HER2-negative disease.
Researchers evaluated the safety and efficacy of abemaciclib plus a non-steroidal AI vs an AI alone among patients with hormone receptor–positive, HER2-negative disease.

Data from the MONARCH 3 trial (ClinicalTrials.gov Identifier: NCT02246621) suggest that initial abemaciclib improves progression-free survival (PFS) among patients with hormone receptor–positive, HER2-negative advanced breast cancer. The findings were published in the Journal of Clinical Oncology.1

Previous data showed that monotherapy with abemaciclib, an orally administered CDK 4/6 inhibitor, improves outcomes among patients with endocrine therapy–refractory disease. For this phase 3 randomized trial, researchers evaluated the safety and efficacy of abemaciclib plus a non-steroidal aromatase inhibitor (AI) vs an AI alone among patients with hormone receptor–positive, HER2-negative disease. The primary endpoint was PFS.

Of 579 patients assessed for eligibility, 493 were randomly assigned 2:1 to receive abemaciclib plus AI (328 patients) or placebo plus AI (165 patients). Patient characteristics were similar between the groups.

With a hazard ratio of 0.54, patients in the abemaciclib arm had a longer median PFS than those who received placebo (not reached vs 14.7 months, respectively; P = .000021). Patients with measurable disease also had a higher objective response with abemaciclib (59%) than with placebo (44%; P = .004).

Five complete responses were observed in the abemaciclib group vs 0 for placebo.

Serious adverse events (AEs) were observed in 27.5% of patients receiving abemaciclib vs 14.9% for placebo. Eight deaths in the abemaciclib arm and 2 in the placebo arm were related to AEs.

As previously reported, diarrhea was the AE most frequently observed with abemaciclib, occurring in 81.3% of patients, though it was usually mild.

Although overall survival data are not yet mature, the researchers concluded that “abemaciclib plus a nonsteroidal AI was an effective initial treatment with a tolerable safety profile for postmenopausal patients with [hormone receptor]-positive, HER2-negative advanced breast cancer.”

Reference

  1. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Oct 2. doi: 10.1200/JCO.2017.75.6155 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters